DRUG DEVELOPMENT |
|
The National AIDS Treatment Advocacy Project - NATAP
- provides the latest in HIV and AIDS drug development and treatment information (on
topics including protease inhibitors, nucleosides, non-nucleosides, double protease
combinations), as well as comprehensive reports and developments from the Fifth
Retroviruses and Opportunistic Infections conference, as well as from the ICAR, ICAAC,
IDSA, European and International HIV and AIDS conferences.
|
|
| NEW ARTICLES |
|
| NNRTI
update: Reports on Efavirenz (EFV); NNRTI Resistance; Nevirapine (NVP)
(04/12/98) |
|
| Reports
on Efavirenz (EFV) includes PK effect of EFV on 141W94; 60 week data
on EFV + Indinavir; 24 week data on EFV + AZT/3TC; and EFV CSF Levels in
Monkeys (04/12/98) |
|
| NNRTI
Resistance Report (O4/12/98) |
|
| Nevirapine
(NVP) Report including 10 month study on NVP + d4T/3TC; NVP + D4T +
NFV (Nelfinavir): preliminary interaction and antiviral activity data; Two
year+ follow-up (INCAS) study of NVP + AZT/ddI;a 24 week study of
NVP+IDV=2 NRTIs;NVP + IDV + 3TC: 1 year follow-up in advanced HIV group
(04/12/98) |
|
| Preliminary
Data on Protease BID Dosing Regimens: Nelfinavir
and Indinavir (04/02/98) |
|
| T-20: A Fusion Inhibitor (03/12/98) |
pdf |
| 1592U89
(Abacavir) Expanded Access Program Announced
(03/12/98) |
pdf |
| Fifth
Retroviruses & Opportunistic Infections Conference, Chicago, February 1-5, 1998 |
|
| Double
Protease Combinations (03/09/98) including: Ritonavir
+ Saquinavir; Nelfinavir + Saquinavir; Indinavir + Nelfinavir; Ritonavir
+ Nelfinavir; 141+IDV, NFV, or SQV; and Commentary on Treating Protease
Resistant Virus. |
pdf |
| 1592
(Abacavir) Resistance and Phenotypic Resistance Testing (03/03/98) |
pdf |
| Reports and
Developments from ICAAC, IDSA, and Hamburg conferences |
|
| Pharmacokinetics
(PK) |
|
| What is Pharmacokinetics (PK)? A
Primer on PK or drug levels in the blood (1/21/98) Read this first! This article will help you
understand "Pharmacokinetics" - a key term referred to in other articles. |
pdf |
| Hydroxyurea
(HU) |
|
| Safety and Antiviral Activity of Hydroxyurea (HU) with ddI (1/21/98) |
pdf |
| Hydroxyurea as a Novel Approach to HIV Therapy, #2 (1/21/98) |
pdf |
| Reduction of the IC50 of ddI by Hydroxyurea (HU) against HIV (1/21/98) |
pdf |
| Hydroxyurea
+ d4T/ddI vs d4T/ddI
(1/21/98) |
pdf |
| Protease
Inhibitors |
|
| Protease Inhibitors & Pediatrics (1/21/98) |
pdf |
| Protease Inhibitors: success
and resistance, salvage therapy, data updates, new Upjohn PI (1/21/98) |
pdf |
| 141W94
(VX-478) (1/21/98) |
pdf |
| In Vitro Effect of HIV Protease Inhibitors on Methadone
Metabolism (1/21/98) |
pdf |
| Twice
Daily Dosing Studies: Indinavir, Nelfinavir, Saquinavir
(1/21/98) |
pdf |
| Crixivan + ddI and d4T (1/21/98) |
pdf |
| Impact
of HIV Protease Inhibitors on HCV Viremia (1/21/98) |
pdf |
| Saquinavir
SGC (Fortovase): EOF, New Formulation (1/21/98) |
pdf |
| Double
Protease combinations |
|
| Double
Protease Combinations
(1/21/98) |
pdf |
| Nucleosides |
|
| 1592U89
(abacavir): efficacy and resistance data (1/21/98) |
pdf |
| Nucleosides: (1) d4T + ddI
following pretreatment with AZT + ddC; (2) ACTG306: d4T + 3TC vs AZT + 3TC; (3) d4T + 3TC
or d4T + ddI vs AZT + 3TC (1/21/98) |
pdf |
| Non-Nucleoside
Treatment Information |
|
| DMP-266: (efavirenz,
Sustiva-brand name) (1/21/98 |
pdf |
| Nevirapine + Indinavir (1/21/98) |
pdf |
| Delavirdine
Interactions with Nelfinavir and Ritonavir: Delavirdine
+ AZT/3TC vs. AZT/3TC (1/21/98) |
pdf |
| Other |
|
Laboratories That Offer the Ultra-sensitive PCR Test to
Individuals (1/21/98) |
pdf |
| MKC-442
and PMEA (1/21/98) |
pdf |
| NATAP Resistance Supplement - Part I (1/21/98) |
pdf |
Salvage Therapy with 6 Drugs (1/21/98) |
pdf |
| T-20 (1/21/98) |
pdf |
The Real Deal on the ICAAC Report by Steven Deeks of 53%
Protease Inhibitors Failure Rate (1/21/98) |
pdf |
| Viral Load Issues and Strategies (1/21/98) |
pdf |
| Effect
of Influenza Vaccination on HIV RNA (1/21/98) |
pdf |
|
Impact
of HAART on Opportunistic Infections (ICAAC) (1/21/98)
|
pdf
|
ARCHIVE OF REPORTS AND DEVELOPMENTS
Read past reports and developments from
various conferences and other sources. |
|
| Post 4th
Retroviruses Conference Reports |
|
| ACTG
316 Perspectives on Vertical Transmission (10/11/97)
|
pdf |
| Virus
Activity in the Lymph Tissue; Reservoirs
of virus (9/30/97) |
pdf |
| Induction/Maintenance:
Hydroxyurea/ddI Therapy in Early Disease (8/25/97)
|
pdf |
| Laboratories
That Offer the Ultra-senstive PCR Test to Individuals (9/25/97)
|
pdf |
| 800
Telephone Number Announced for 3 1592U89 Compassionate Use Programs
(8/8/97) |
pdf |
| 1592U89:
Cross-Resistance With Nucleosides and Expanded Access and CNS Penetration
in Animal Models (7/29/97) |
pdf |
| FDA
Receives Reports of 83 Cases of Diabetes Like Symptoms for Individuals Taking
Protease Inhibitors (6/18/97)
|
pdf |
| Reports
from FDA, ICAR, and other sources |
|
| FDA
Proposal: Using Viral Load in AIDS Clinical
Trials (5/25/97) |
pdf |
| Report
of Day 2 From FDA: ADAC Hearing on Using
Viral Load as an Endpoint in Studies (8/28/97)
|
pdf |
| First
Oral PMPA Study Starts (5/8/97) |
pdf |
| Bis-Pom
PMEA (5/3/97) |
pdf |
| PMPA:
first human data (5/3/97) |
pdf |
| 10th
International Conference on Antiviral Research (ICAR) (5/3/97)
|
pdf |
| Glaxo
Wellcome announces 1592U89 Compassionate Use Program |
pdf |
| d4T
+ ddI -- for treatment-naive (modified
5/3/97) |
pdf |
| Merck
Study 028 Stopped: Preliminary Data (4/23/97) |
pdf |
| Nucleoside
Resistance and Cross-Resistance (4/12/97)
|
pdf |
| Mutations
in HIV-1 protease associated with drug resistance (modified
5/9/97) |
pdf |
| Nelfinavir
(modified 4/29/97) general information, study
results (CD4 and viral load), dosing schedule, eating instructions, drug
interactions, combination with other protease inhibitors and NNRTIs, side
effects, resistance, cross-resistance |
pdf |
| d4T+
ddI for Individuals with Prior Treatment-Experience (added
3/24/97) |
pdf
|
| Viracept
Approved for Adults and Children and Ritonavir Approved for Children
(added 3/24/97) |
pdf
|
| Hydroxyurea
with ddI or ddI/d4T: a novel
approach to HIV therapy (added 3/14/97)
|
pdf |
| Ritonavir
+ Saquinavir: 24 week data
(3/11/97) |
pdf |
| Altis
I & II: a pilot open label
study of d4T/3TC in treatment-naive and experienced individuals (3/9/97)
|
pdf |
|
MKC-442
(3/9/97)
|
pdf
|
| 1592
expanded access announcement (3/5/97)
|
pdf
|
| The
Duration of Viral Suppression is predicted by Viral Load During Protease
Therapy (2/27/97)
|
pdf |
| ACTG
320 stopped due to convincing data demonstrating clinical superiority
(2/27/97)
|
pdf |
| DMP-266:
an NNRTI; early safety and efficacy data (modified 1/31/97) |
pdf |
| POST
BIRMINGHAM CONFERENCE REPORTS |
|
| 141W94
double protease inhibitor study & brief protease therapy discussion
(1/15/97) |
pdf |
| Access
programs to viral load testing from Chiron and Roche
(1/15/97) |
pdf |
| Ritonavir
plus AZT plus ddC (1/8/97)
|
pdf |
| Ritonavir
plus AZT plus 3TC (1/8/97)
|
pdf |
| Ritonavir
plus saquinavir (1/8/97)
|
pdf |
| POST
VANCOUVER TREATMENT REPORTS |
|
| Nevirapine
Interaction Data with Indinavir
(11/26/96) |
pdf |
| Consensus
Statement on 1592 Expanded Access and Accelerated Approval (11/24/96)
|
pdf |
| Delavirdine
FDA Hearing (11/24/96) |
pdf |
| Merck
Announces Extension of Temporary Tracking Distribution System
(modified 11/11/96) |
pdf |
| Preliminary
results of ongoing delavirdine-protease inhibitor interaction studies
---exact text of description from Pharmacia & Upjohn (10/6/96) |
pdf |
| Agouron
Announces Expanded Access Program
(9/17/96) |
pdf |
| Nevirapine
Update (9/17/96)
|
pdf |
| Nelfinavir
Pediatrics Study (9/17/96)
|
pdf |
| Delavirdine
Interaction Studies -- Caution! (9/17/96) |
pdf |
| Nelfinavir:
Preliminary Efficacy & Safety Data Update (9/3/96) |
pdf |
| Perspectives
on Viral Load (HIV RNA) and When to Initiate Therapy
(8/26/96) |
pdf |
| PMPA
Update (8/14/96)
|
pdf |
| Nelfinavir
Resistance Profile (8/15/96)
|
pdf |
| 1592U89:
An update of preliminary safety & antiviral data (8/9/96) |
pdf |
| Newly
Infected Subjects: Triple
Therapy with AZT/3TC and Ritonavir (modified 11/16/96) |
pdf |
| Combination
Use of Ritonavir and Saquinavir in HIV-Infected Patients
(8/5/96) -Preliminary Safety and
Activity Data |
pdf |
| Stavudine
(d4T) and Didanosine (ddI) Combination Therapy in HIV-Infected Subjects
(8/5/96) Antiviral Effect and
Safety in an On-going Pilot Randomized Double-Blinded Trial |
pdf |
| Indinavir+AZT/3TC:
Merck's study #035 (8/5/96) |
pdf |
| Antiretroviral-Naive
Subjects Chronically Infected With HIV-1
(7/22/96) Triple therapy with nelfinavir in combination with AZT and 3TC
-- Vancouver Abstract L.B.B. 6031, Martin Markowitz et al |
pdf |
| Ritonavir,
ddC and AZT:
(7/18/96) Abbott French Study #208 of Triple Therapy, presented at Vancouver
Abbott Symposium July 10, 1996 |
pdf |
| OTHER
ARTICLES |
|
| Can
HIV be "eradicated" From the Infected Individual? June 28, 1996 |
pdf
|
| Pre-Vancouver
Protease Inhibitor Update: combination & sequential use of protease inhibitors June
25, 1996 |
pdf
|
| Viracept (nelfinavir, aka AG-1343): Agouron's
Protease Inhibitor (06/14/1996) |
pdf |
| Life
or Death: ADAP (6/18/96) |
pdf |
| Viral Load (HIV RNA): Important
Information (6/10/96) |
pdf |
| Nevirapine: Accelerated Approval
Recommended for adults by the advisory committee (6/9/96) |
pdf |
| Viral Load --FDA approves test
(06/03/1996) |
pdf |
| 1592U89
--A New Antiviral For HIV in Development (4/22/96) Glaxo Wellcome's nucleoside
reverse transcriptase inhibitor in early studies. |
pdf |
| Drug
Interactions with Norvir (ritonavir) (4/10/96)
table of contraindicated drugs and equivalents. If you don't have a browser
that allows tables, view list
file. See also
Novir dosing up schedule. |
pdf |
| Ritonavir: Important
Information (4/5/96) interactions, resistance, saquinavir combination trial |
pdf |
| Delavirdine Expanded Access (4/4/96) drug interactions you need to be aware of |
pdf |
| Merck and Abbott FDA Advisory Panel Hearings (2/28-3/1/96) includes discussion of expanded access, future considerations, new drug
indications, cross-resistance, Abbott hearing, Merck hearing,
ddI--AZT/ddI--AZT/ddC, viral
load testing. |
pdf |
| Community Meeting with Merck (2/26/96) discussion of New Drug
Application for Merck's protease inhibitor, indinavir (Crixivan) |
pdf |
| Community Meeting with Abbott (2/20/96) discussion of New Drug
Application for Abbot's protease inhibitor, ritonavir |
pdf |
| Viral
Load Testing (12/95) understanding and using it, and FDA approval |
pdf |
| Cross-Resistance and Protease Inhibitors (1/96) |
pdf |
| Primer on Protease Inhibitors (1/96) |
pdf |
| The Upjohn Protease Inhibitor (1/96) |
pdf |
| New Studies for Glaxo's Vertex (12/14/95) |
pdf |
| Report of the FDA Hearings (11/10/95) for approval of
AZT/3TC, saquinivir and D4T |
pdf |
|
|
You
can download these files to your computer with Adobe Acrobat Reader
(TM) format for easy printing by clicking on pdf .
To download Adobe Acrobat Reader software for free, click on the icon below.. |
